Last November, we had a discussion/presentation focusing on IP efficiency, reads overlapping protein binding sites
Since then, different batch of antibodies have been tested (K27ac, CTCF) for PLAC-seq.
Briefly, for CTCF, three Abs were chosen. 1 from Cell Signaling and 2 from Santa Cruz. The one from Cell Signaling has the best yield of all the three. Santa Cruz antibodies appear to have lower binding affinity as well. Cell Signaling antibody is currently chosen
The catalog number of the antibodies being chosen will be shared to the WG after the robust level of them has been assessed.
Yijun Ruan presented ChIA-PET2 last December and it appears to be very similar to PLAC-seq and HiChIP
PLAC-seq/HiChIP reduces noise level. But the antibody pull-down is observed to be more sensitive.
The main difference between ChIA-PET1 and PLAC-seq/HiCHIP/ChIA-PET2 is in the order of ChIP and in-situ ligation. Therefore, the current discussion about antibodies for PLAC-seq and HiChIP is probably applicable to ChIA-PET2 as well.
There are other differences in the analytic workflow, though. For example, ChIA-PET2 uses specific adapters so they needs to be seeked out during analysis.
It is assumed that Yijun Ruan’s group will be using the updated protocol ChIA-PET2 within the ENCODE project. Erez will confirm this with Yijun. Once confirmed, OMICS will plan to add ChIA-PET2 with PLAC-Seq and HiChIP.